Mortality in Non-cystic Fibrosis Bronchiectasis

Mortality in Non-cystic Fibrosis Bronchiectasis: a Long-term Cohort Analysis

In this study we analyzed the overall survival for all newly diagnosed patients with non-cystic fibrosis bronchiectasis from June 2006 onwards. The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa and evaluate the impact on survival of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension.

Study Overview

• Status: Completed
• Conditions: Non-cystic Fibrosis Bronchiectasis

• Study Type: Observational
• Enrollment (Actual): 253

Contacts and Locations

Study Locations

• Belgium
  • Vlaams-Brabant
    • Leuven, Vlaams-Brabant, Belgium, 3000
      • UZ Leuven

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

non-cystic fibrosis bronchiectasis

Description

Inclusion Criteria:

• Patients with clinically significant and radiologically proven bronchiectasis
• Chest CT scan confirming the presence of bronchiectatic lesions and had symptoms of chronic productive cough
• Bronchiectasis was deemed to be present if there was one or more of the following criteria: a bronchoarterial ratio greater than 1, lack of tapering of the bronchi and visualization of bronchi within 1 cm of costal or paravertebral pleura or abutting the mediastinal pleura

Exclusion Criteria:

• diagnosis of cystic fibrosis
• underlying tumoral problem causing the bronchiectatic lesions (postradiotherapy, secondary immunodeficiency due to chemotherapy or postinfectious due to tumoral obstruction)
• patients with asymptomatic traction bronchiectasis caused by interstitial lung disease

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
overall survival	6 years 4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
risk factor identification for NCFB	The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa.	6 years 4 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identify cause of death	If death occurred, the patient file was reassessed to identify cause of death.	6 years 4 months
risk factor identification for the survival of NCFB	The investigators will evaluate the impact of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension on survival .	6 years 4 months

Collaborators and Investigators

• Sponsor: Universitaire Ziekenhuizen KU Leuven

Study record dates

Study Major Dates

• Study Start: June 1, 2006
• Primary Completion (Actual): October 1, 2012
• Study Completion (Actual): December 1, 2012

Study Registration Dates

• First Submitted: February 13, 2013
• First Submitted That Met QC Criteria: February 13, 2013
• First Posted (Estimate): February 15, 2013

Study Record Updates

• Last Update Posted (Estimate): February 20, 2013
• Last Update Submitted That Met QC Criteria: February 18, 2013
• Last Verified: February 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Bronchial Diseases; Fibrosis; Bronchiectasis
• Other Study ID Numbers: B51060 (OTHER: Belgium: Institutional Review Board); B32220084152 (Belgium: Institutional Review Board)